Heat shock proteins (HSPs) are
molecular chaperones that are consistently increased to help cells survive under conditions of stress. As a member of the Hsps, Hsp90 is involved in
protein post‑translational maturation and disposition. This
protein is ubiquitously expressed in normal cells. However, in
cancer cells and particularly in
hematological malignancies, Hsp90 is unexpectedly abundant to maintain levels of
proteins vital for
cancer pathology. Hsp90 inhibitors can target the
ATP domain of Hsp90 and prohibit its exchange of
ADP for
ATP, leading to the degradation of client
proteins and disruption of signaling cascades. Concomitantly, Hsp90 inhibitors induce
tumor cell apoptosis, promote cell cycle arrest and abrogate microenvironment‑derived cytoprotection.
Geldanamycin, a
benzoquinone antineoplastic antibiotic isolated from the bacterium Streptomyces hygroscopicus, and its derivative, 17‑AAG, were first developed as Hsp90 inhibitors and exhibited effective anticancer potency. Whereas, severe side effects and low solubility restricted their application at the clinical level,
BIIB021, a novel and fully synthetic inhibitor of Hsp90, is water soluble and well‑tolerated. Beyond degrading oncogenic
protein,
BIIB021 can overcome multidrug resistance and potentiate the effects of other
therapeutics. phase I/II trials have been conducted to evaluate the dosing schedules and activity of this agent. The present review focuses on the antitumor profile of
BIIB021. Furthermore, given the promising efficacy of
BIIB021 in
leukemia and
lymphoma, this review also discusses current research concerning the treatment of
hematologic malignancies by targeting Hsp90.